Sign in to view content

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2024

Related

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial
Jason Hsu, MD
Annual Meeting Talks
2021
Assessment of the Inclusion of Racial/Ethnic Minorities in Retina Clinical Trials
Vivienne S. Hau, MD, PhD
Updates from the Field
2022
Safety of Intravitreal Pegcetacoplan for Geographic Atrophy: 12-Month Results of the OAKS and DERBY Trials
Caroline Baumal, MD
Annual Meeting Talks
2022

Category: Hereditary Retinal Disease & Genetics

See more